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Abstract 
Cutaneous adverse drugs reactions (CADRs) are quite usual among ADRs. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are one of the common and predictable causes of cutaneous adverse reactions (CADR’s). NSAIDs can 
cause multiple cutaneous complications like urticaria, angioedema, acneiform eruption, stevens johnson syndrome 
(SJS), toxic epidermal necrolysis (TEN), vasculitis, fixed drug eruption (FDE) etc. NSAIDs are very frequently 
prescribed drugs and even one of the frequent over the counter sold medications, making it more critical to have a 
more particular knowledge about the wide spectrum of cutaneous complications it can cause. The present case series 
focuses on the conglomeration of the few cases of cutaneous complications experienced by the patients on NSAID 
therapy. 
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Introduction 
Adverse reactions to medications are common and 
often manifest as a cutaneous eruption. Cutaneous 
adverse drug reactions may manifest as urticaria, 
hypersensitivity syndrome, photosensitivity, SJS, TEN 
or FDE (fixed drug eruption).  
__________________ 
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FDE is an immunological response to a drug, 
characterized by the development of oval or annular 
erythematous patches following systemic exposure to a 
drug which resolve with hyperpigmentation. FDE are 
responsible for 10% of all adverse drug reactions and 
occur in all ages, more commonly seen in young adults 
[1]. FDE manifests as recurrent eruptions characterized 
by erythematous to violaceous macules that 
subsequently progress to a plaque. FDE are one of the 
commonest adverse drug reactions encountered by 
clinicians in their day to day practice. Though not fatal, 
FDE can cause cosmetic embarrassment especially as 
the tend to recur on the previously affected sites 
leaving behind residual hyperpigmentation. The lesions 
usually vary in size and can involve any part of the skin 
[1]. The pathogenetic mechanism underlying FDE is 
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still enigmatic. The patho-mechanism involves an 
antibody-dependent, cell-mediated cytotoxic response. 
The most commonly accepted hypothesis is the 
persistence of memory T cells in the affected skin. 
Diclofenac is a most commonly used NSAIDs, a 
phenylacetic acid derivative. It has got analgesic, 
antipyretic and anti-inflammatory activities [2]. 
Stevens-Johnson Syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are life-threatening, immune-
mediated reactions to drugs characterized by epidermal 
necrosis, extensive detachment of the epidermis, 
erosions of mucous membranes and severe 
constitutional symptoms [3,4].  
Adverse drug reactions due to NSAIDs are numerous, 
but cutaneous adverse reactions also warrant special 
attention. The lack of proper diagnostic tests, makes 
the diagnosis yet more difficult. The clinician has to 
depend on physical examination rather than definite 
laboratory investigation for confirmation. 
Case 1 
 
A hypertensive, non diabetic woman, of 47 yrs 
presented with dark, violaceous, erythematous, slightly 
edematous plaque over her left hand [Fig 1a, b]. The 
reaction was seen after consumption of a fixed dose 
combination (aceclofenac 100 mg with paracetamol 
325 mg) drug for two days. It was an OTC drug which 
the patient had taken for her knee pain. She had similar 
lesions in the same site before. However, she denies of 
history of allergy in her family. There were no 
associated symptoms like fever, body ache or any other 
mucosal involvement. Other laboratory parameters 
were normal. The case was diagnosed as bullous fixed 
drug eruption probably due to intake of aceclofenac. 
The medication was withdrawn and she was advised to 
take oral antihistamine levocetrizine 5 mg OD. The 
skin lesions subsided and disappeared without 
complications. 
 
Figure 1 a, b: Bullous fixed drug eruption (dark, violaceous, erythematous, slightly edematous plaque) over 
her left hand 
Case 2 
A 42 years old, non-hypertensive non diabetic male 
presented with of violaceous round to oval painless 
mildly pruritic erythematous plaques on abdomen. The 
cutaneous complication ensued 2 days after 
consumption of diclofenac 50 mg tablets indicated for 
osteoarthritis pain. The lesions were mildly pruritic and 
confined to abdominal area only. There was no other 
area involved. The patient has similar experience of 
cutaneous reaction before. There was no positive 
familial history of known drug allergy. Other 
laboratory findings were within normal limits. The 
medication was withdrawn and he was put on oral 
antihistamine cetrizine 10 mg OD. The lesions resolved 
within 10 days after stoppage of the suspected 
medication. The provisional diagnosis was made as 
pigmenting type fixed drug eruption, probably due to 
intake of diclofenac [Fig. 2a,b]. 
        
Figure 2a, b: Fixed drug eruptions 
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Case 3 
A 33-year-old, non-diabetic, non-hypertensive male 
presented with a history of mildly pruritic rash for three 
days. To start with the rash was confined to orofacial 
area but soon involved distal aspect of forearm, and 
lateral aspect of neck. On examination, it was found to 
be well-defined erythematous plaques of varied sizes 
involving the orofacial area, distal aspect of right 
forearm, and lateral aspect of neck. The patient gives a 
history of intake of fixed dose combination (FDC) 
aceclofenac 100, paracetamol 325-FDC), twice daily) 
four days back. He had similar lesions at the same site 
before due to the intake of same medication of another 
brand. There was no significant family history of drug 
allergy. The suspected drug was withdrawn, and patient 
was advised oral antihistamines and topical steroids 
with complete recovery in 14 days. Provisional 
diagnosis was provisional pigmenting type fixed drug 
eruption probably due to intake of aceclofenac.
 
 
Figure 3 a, b: Fixed drug eruptions (pigmentory type) 
Case 4 
A 24 yr old non-hypertensive non-diabetic female 
presented with hemorrhagic crusted lesions all 
throughout her body with oro-mucocutaneous ulcers 
desquamation of skin over lips, after consumption of 
aspirin 350 mg tabs as over the counter (OTC) for three 
days [Figure 4a, b]. To start with these lesions were 
erythematous, nontender, itchy associated with fever. 
The lesions first appear in face but soon involved other 
parts of the body as well. Two days after the rash 
patient had experienced formation of blisters in the 
same region, followed by hemorrhagic crusted lesions 
and desquamation of the skin. She continued to have 
fever and was taking oral Paracetamol. On examination 
it was found to have a body surface involvement of 
about 61%, hemorrhagic crusted lesions were prevalent 
all over face(involving inner mucosal areas), extensor 
surface of upper extremity. There was also conjunctival 
involvement for which ophthalmologists advise was 
taken. Her laboratory reports were normal. There was 
mild leucocytosis. She was managed conservatively 
with iv. fluids, antibiotics for a short course, 
cyclosporine 100 TDS. She was discharged after a 
hospital stay of 24 days with favorable conditions. A 
provisional diagnosis was made: a case of TEN 
probably due to intake of aspirin. 
                   
Figure 4a, b: A case of TEN, presented with hemorrhagic crusted lesions all throughout her body with oro-
mucocutaneous ulcers desquamation of skin over lips 
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Case 5 
A 48 year old male presented with 2 day history of 
multiple fluids filled mildly pruritic purplish blisters 
over the right hand shoulder. The lesions had appeared 
after consumption of oral etoricoxib 30 mg BD which 
was prescribed to him by the orthopedic physician. O/E 
multiple purplish- bullae was found over the fingers of 
right hand and over shoulder. Patient had past history 
of some drug allergy due to some unknown 
medications. He was afebrile and his vitals were within 
the normal range. He was treated with oral 
corticosteroids with an advice to strictly avoid the drug 
in future. The lesions resolved within 14 days after 
stoppage of the suspected medication. He was 
provisionally diagnosed as a case of bullous FDE 
probably due to intake of etoricoxib [Fig. 5a, b]. 
                                                
Figure 5a, b: Bullous FDE 
Discussion 
Cutaneous presentation is possibly the most common 
manifestation of adverse reactions to a drug [5]. 
It may manifest as urticaria, angioedema, fixed drug 
eruption or maculopapular rash. Of these, 2% are 
severe, and a few even poor outcomes [6]. Severe 
cutaneous adverse reactions (SCARs) include Stevens-
Johnson syndrome (SJS), toxic epidermal necrolysis 
(TEN), drug reaction with eosinophilia and systemic 
symptoms (DRESS) and acute generalized 
exanthematous pustulosis. SCARs can be life-
threatening, with mortality rates ranging from 23% to 
45% for patients with TEN and 10% for those with 
DRESS [7, 8]. NSAIDs are known to be the most 
frequently prescribed medications worldwide, and are 
also thought to be leading agents of drug adverse 
reactions [9, 10]. NSAIDs may invoke immunological 
reactions, mediated by IgE, which arise due to 
activation of T cells [11, 12]. A wide spectrum of 
cross-reactions among NSAIDs is widely known, 
which may be an immediate hypersensitive response, 
manifesting as asthma, urticaria, angioedema and even 
anaphylaxis. However, there is lack of evidence 
concerning the cross reactivity of different NSAIDs. 
The pathophysiology of SCARS is not completely 
understood yet. It has been found that major type of 
hypersensitivity reactions due to NSAIDs happen to be 
cross tolerant, which is related to an imbalance in the  
 
 
arachidonic acid pathway that leads to COX-1 
inhibition. 
In the above case series majority of cases were 
diagnosed as fixed drug eruptions, and there was only 
one case of TEN. Clinical diagnosis was made by the 
treating physician. Causality assessment was done by 
Naranjo scoring scale and all were “probable” 
category. The severity of all were assessed by Hartwig 
Seigel Scale and found to be moderate in majority of 
cases and severe for one case. All the events were 
reported under Pharmacovigilance Programme of India 
[PvPI].Management includes delineating the causative 
drug through a detailed medication history, along with 
other allergic laboratory investigations Drug 
sensitization is advised in few cases where benefit 
outweighs risk, but seldom practiced. Management 
includes prompt withdrawal of the offending agent, 
followed by use of topical steroids, or disease specific. 
SCARs may necessitate the use of immunomodulatory 
agents such a cyclosporine, and even systemic steroids. 
 
Conclusion 
NSAIDs being widely prescribed and known to be a 
frequent OTC drug are not devoid of complications. 
Cutaneous adverse reactions, commonly experienced 
as adverse effect of NSAIDs consumption, should be 
managed with prompt withdrawal of the putative drug. 
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Avoidance of the similar drug through proper patient 
counseling may avoid such complications in future. 
The diagnosis of drug allergy has by far been clinical 
with little or no scope for confirmation through 
laboratory tests. Admittedly, the detailed understanding 
of drug allergy cases has been in general constrained 
with a relative lack of access to standardized laboratory 
diagnostic tests. 
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